- Fund Type: Closed-End Fund
- Objective: Sector Fund-Health & Biotech
- Asset Class: Equity
- Geographic Focus: Global
Snapshot for BB Biotech AG (BION)
| Open: | - | High - Low: | - | Primary Exchange: | Equiduct |
|---|---|---|---|---|---|
| Volume: | 0 | 52-Week Range: | 88.1000 - 121.9000 | Beta vs NBI: | - |
Fund Profile & Information for BION
BB Biotech AG is an investment company. The Company invests in biotech companies that operate in areas that include oncology, cardiovascular diseases, infectious diseases and autoimmune diseases.
| Inception Date: | Telephone: | Tel: +41 44 267 67 00 | |
|---|---|---|---|
| Managers: | DANIEL KOLLER | ||
| Web Site: | www.bbbiotech.ch/en/bb-biotech/ | ||
Fundamentals for BION
| NAV | - |
|---|---|
| Assets (M) | (on 2002-12-31) 1,579.0000 |
| Shares out (M) | 0.00 |
| Market Cap (M) | 0.00 |
| % Premium | - |
| Average 52-Week % Premium | - |
| Fund Leveraged | N |
Dividends for BION
No dividends reported
Performance for BION
| 1-Month | +12.56% | 1-Year | - |
|---|---|---|---|
| 3-Month | +26.26% | 3-Year | - |
| Year To Date | +37.74% | 5-Year | - |
| Expense Ratio | - |
Top Fund Holdings for BION
Filing Date: 03/31/2012| Name | Position | Value | % of Total |
|---|---|---|---|
| Celgene Corp | 2,600,000 | 181,900,000 | 16.293% |
| Actelion Ltd | 4,226,115 | 139,500,000 | 12.496% |
| Vertex Pharmaceuticals Inc | 2,822,684 | 104,500,000 | 9.360% |
| Gilead Sciences Inc | 4,220,000 | 93,000,000 | 8.330% |
| Incyte Corp Ltd | 4,980,000 | 86,700,000 | 7.766% |
| Novo Nordisk A/S | 591,056 | 73,900,000 | 6.619% |
| Isis Pharmaceuticals Inc | 7,233,800 | 57,200,000 | 5.124% |
| Halozyme Therapeutics Inc | 4,800,000 | 55,300,000 | 4.953% |
| Amylin Pharmaceuticals LLC | 2,323,391 | 52,300,000 | 4.685% |
| ImmunoGen Inc | 3,666,300 | 47,600,000 | 4.264% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page